Allecra Therapeutics, in our BioDiscovery portfolio, announced that its investigational product EXBLIFEP (cefepime-enmetazobactam) met the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) prespecified primary endpoint in the Phase 3 ALLIUM clinical trial in patients with complicated urinary tract infections (cUTI), including acute pyelonephritis (AP). In addition, EXBLIFEP demonstrated superiority over piperacillin-tazobactam.

To read the press release, please Allecra Therapeutics PIII_25Feb2020

Share on :

More news